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A B S T R A C T
Empirical evidence suggests that levodopa medication used to treat the motor symptoms of Parkinson's disease
(PD) may either improve, impair or not aﬀect speciﬁc cognitive processes. This evidence led to the ‘dopamine
overdose’ hypothesis that levodopa medication impairs performance on cognitive tasks if they recruit fronto-
striatal circuits which are not yet dopamine-depleted in early PD and as a result the medication leads to an
excess of dopamine. This hypothesis has been supported for various learning tasks including conditional
associative learning, reversal learning, classiﬁcation learning and intentional deterministic sequence learning,
on all of which PD patients demonstrated signiﬁcantly worse performance when tested on relative to oﬀ
dopamine medication. Incidental sequence learning is impaired in PD, but how such learning is aﬀected by
dopaminergic therapy remains undetermined. The aim of the current study was to investigate the eﬀect of
dopaminergic medication on incidental sequence learning in PD. We used a probabilistic serial reaction time
task (SRTT), a sequence learning paradigm considered to make the sequence less apparent and more likely to be
learned incidentally rather than intentionally. We compared learning by the same group of PD patients (n=15)
on two separate occasions following oral administration of levodopa medication (on state) and after overnight
withdrawal of medication (oﬀ state). Our results demonstrate for the ﬁrst time that levodopa medication
enhances incidental learning of a probabilistic sequence on the serial reaction time task in PD. However, neither
group signiﬁcantly diﬀered from performance of a control group without a neurological disease, which indicates
the importance of within group comparisons for identifying deﬁcits. Levodopa medication enhanced incidental
learning by patients with PD on a probabilistic sequence learning paradigm even though the patients were not
aware of the existence of the sequence or their acquired knowledge. The results suggest a role in acquiring
incidental motor sequence learning for dorsal striatal areas strongly aﬀected by dopamine depletion in early PD.
1. Introduction
Levodopa medication has been described as the most signiﬁcant
advance in the treatment of Parkinson's disease (PD) (Olanow et al.,
2004; Poewe, et al., 2010; Stocchi, 2005). By ameliorating the eﬀects of
dopamine depletion in the basal ganglia, levodopa can improve the
major motor symptoms with considerable beneﬁts for patients’ quality
of life. Nonetheless, the consequent widespread increase in dopamine
levels can impair functions in brain networks that are relatively spared
in the early stages of the disease, such as the limbic and orbitofrontal
striatal circuits. This ‘dopamine overdose’ can result in cognitive
deﬁcits that have a negative impact on the quality of life of patients
with the disease (Schrag et al., 2000). Fundamental processes such as
learning and memory have been linked to dopamine release, especially
within the pre-frontal cortex and striatum (see for example Gabrieli,
1998; Packard and Knowlton, 2002; Shohamy et al., 2008; Williams
and Goldman-Rakic, 1995). Therefore, studying such eﬀects has
potentially important implications for the management of PD as well
as increasing our theoretical understanding of the role of dopamine in
modulating neural pathways instantiating cognition and learning.
Incidental procedural learning is the gradual acquisition of a
cognitive or motor skill in long-term memory through repetitive task
performance (Nissen and Bullemer, 1987; Reed and Johnson, 1994;
Shanks et al., 2003). In contrast, intentional declarative learning
involves the active acquisition of factual knowledge. Incidental motor
learning has been widely investigated using the serial reaction time
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task (SRTT). Typically, in this task, participants respond to the
appearance of a target at one of several locations by pressing the
corresponding response button without knowing that the targets follow
a pre-determined sequence (Nissen and Bullemer, 1987). Learning of
the sequence is demonstrated by the speeding up of reaction times
(RTs) on sequence relative to random (or pseudorandom) trials. Many
researchers argue that such learning can occur in the absence of
awareness due to the existence of good incidental learning in normal
participants who cannot demonstrate explicit awareness of the se-
quence structure (Berns et al., 1997; Cleeremans et al., 1998; but see
also Shanks et al. (2003), Shanks (2004)) and the presence of relatively
preserved incidental learning in patients with intentional learning
deﬁcits, such as Korsakoﬀ's syndrome (Nissen and Bullemer, 1987)
and Alzheimer's (Knopman and Nissen, 1987). Nonetheless, research-
ers concede that parallel mechanisms of intentional (explicit) learning
may be engaged in SRTTs if the sequence structure is insuﬃciently
concealed (Rowland and Shanks, 2006; Shanks et al., 2005).
Interest in incidental motor sequence learning in patients with PD
has been fuelled by studies in normal participants that both identify
task-related activity in brain networks known to be aﬀected by PD and
suggest a signiﬁcant role for dopamine in task performance. Functional
imaging studies of incidental SRTT in healthy participants relate
performance to change in activation within the basal ganglia, especially
the caudate and putamen (Grafton et al., 1995; Rauch et al., 1997;
Schendan et al., 2003; Willingham et al., 2002), and to cortical regions
associated with the fronto-striatal network, including the pre and
supplementary motor areas (SMA) (Grafton et al., 1995; Hazeltine
et al., 1997; Honda et al., 1998) and, during early stages of learning,
the dorsolateral prefrontal cortex (DLPFC) (Meehan, et al., 2011).
Furthermore, a systematic release of dopamine in the left putamen and
bilaterally in the anterior caudate during SRTT performance has been
documented using PET to measure changes in the concentration of the
dopamine receptor ligand 11C-raclopride (Badgaiyan et al., 2007).
Learning was attributed to activity in the left caudate as it was not
found in a matched motor planning task, whilst the activity common to
both tasks (left putamen and right caudate) was proposed to underlie
movement selection. Finally, the administration of raclopride (a D2
antagonist) produces impairment in learning proportional to the dose
administered (Tremblay et al., 2009). Taken together, these studies
indicate that learning on the SRTT relies on the striatal motor and
associative circuits known to be adversely aﬀected by dopamine
depletion in PD, and that successful learning appears to be related to
a systematic release of dopamine. Nonetheless, as the relation of
dopamine to performance is described by an inverted U curve, where
too little or much dopamine may be detrimental to performance, it is
unclear the degree to which patients with PD will be impaired on SRTT
learning on or oﬀ medication (Cools et al., 2001; Goldman-Rakic,
1999; Williams and Goldman-Rakic, 1995).
Several studies have investigated performance of the SRTT in
patients with PD on levodopa therapy. The majority reported impaired
learning compared to age matched controls (e.g. Brown et al., 2003;
Jackson et al., 1995; Kelly et al., 2004; Muslimovic et al., 2007; Shin
and Ivry, 2003; Wilkinson et al., 2009), but a few studies found little
diﬀerence between PD and control groups (Doyon et al., 1997; Feigin
et al., 2003). Nonetheless, a meta-analysis of SRTT studies in PD
patients taking L-Dopa concluded that learning was impaired (Siegert
et al., 2006). However, it is not possible to diﬀerentiate, on the basis of
these studies, the degree to which impairments were a consequence of
the disease or its medical treatment with dopamine replacement
therapy.
Only two studies have speciﬁcally reported data on SRTT learning
in PD patients who were either not taking levodopa (Muslimovic et al.,
2007) or tested oﬀ-medication after a washout period (Wilkinson and
Jahanshahi, 2007). In the ﬁrst study, Muslimovic and colleagues
(2007) assessed learning in a large sample of PD patients (n=95)
performing a 10 item SRTT. The patients displayed some sequence
learning but this was attenuated in comparison to healthy age matched
controls. Yet, the learning for a subgroup of ‘de novo’ patients (n=24)
who were not receiving dopamine therapy was indistinguishable from
aged matched participants. However, in examining a sub-group of ‘de
novo’ patients who did not require levodopa as yet, the eﬀects of
medication are inextricably confounded with disease stage and severity
in this study. This is demonstrated by the non-medicated patients
being signiﬁcantly more recently diagnosed and less impaired (on both
the Hoehn and Yahr and UPDRS scales) compared to the remaining
patients. Furthermore, on the SRTT the non-medicated patients had
similar overall RTs to control participants whereas medicated patients
were signiﬁcantly slower. In the second study, Wilkinson and
Jahanshahi (2007) demonstrated that SRTT learning in PD patients
(treated with dopaminergic medication) tested oﬀ dopaminergic med-
ication was impaired compared with healthy age matched controls.
Hence, this suggests that impaired learning on the SRTT can occur as a
function of the disease and not simply as a side-eﬀect of the medica-
tion. However, patients were only tested oﬀ-medication and compar-
isons of the magnitude of the eﬀect with published studies are not
really possible due to large inter-individual variability in the presenta-
tion of the disease and the considerable diﬀerences in task procedures
across studies. As a consequence, the relationship between impair-
ments in PD patients on and oﬀ dopamine medication remains
undetermined.
The current study aims to address the eﬀects of PD and levodopa
medication on incidental motor sequence learning by assessing the
same group of patients both on and oﬀ dopamine medication. As
learning on the task is likely to be mediated by both the motor and
associative fronto-striatal circuits, it was predicted that similar to the
motor symptoms of PD, sequence learning would be greater on
medication compared to the oﬀ state. Importantly, the study uses an
SRTT in which the sequence is presented probabilistically, which is
considered ideal for minimising explicit knowledge of the sequence and
ensure the sequence learning remains implicit (Cleeremans and
McClelland, 1991; Stadler, 1992).
2. Methods
2.1. Participants
Fifteen individuals (13 male; 14 right handed and one ambidex-
trous) meeting the Parkinson's Disease Society Brain Bank diagnostic
criteria for idiopathic PD (Hughes et al., 1992) gave written informed
consent to participate, which included the willingness to be assessed
prior to taking medication following an overnight washout period (see
below). They received reimbursement for travel expenses. Ethics
approval for the study was obtained from the Joint Ethics Committee
of the UCL Institute of Neurology & the National Hospital for
Neurology and Neurosurgery. Informed consent was obtained from
all participants. Participants were aged between 54 and 75 (M=67.1,
SD=6.1), had been diagnosed for between 3 and 21 years (M=8.9,
SD=5.3) and were classiﬁed by a neurologist as being in the mild to
moderate stages of the disease, i.e. with Hoehn & Yahr (1967) scores
between 1 and 3 (M=1.8, SD=.7). Severity of motor symptoms was
assessed using the motor section of the Uniﬁed Parkinson's Disease
Rating Scale (UPDRS, part III Fahn & Elton, 2005) with scores
ranging between 12 and 62 (M=30.8, SD=13.8) oﬀ medication and
between 5 and 39 (M=15.0, SD=8.8) on medication. Participants were
non-demented with mean scores on the Mini-Mental State
Examination (Folstein, Folstein, & McHugh, 1975) of 29.4 (SD=.7)
and non-depressed with average scores of 7.43 (SD=3.7) on the Beck
Depression Inventory (Beck, et al. 1961). Pre-morbid IQ was estimated
using the National Adult Reading test (Nelson and O'Donnell, 1978).
All participants were taking levodopa (Sinemet, Madopar or Staleva)
and the mean levodopa equivalent daily dose (LEDD) was 694.89
(SD=462.44) milligrams (Tomlinson et al., 2010). Information about
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the patients is presented in Table 1. Patient data was compared to that
of thirteen control participants (5 male, all right handed, mean
age=55.1 SD=10.1) with no history of neurological or psychiatric
illness, head injury or alcohol or drug abuse who were also tested on
two occasions to control for potential practice eﬀects.
2.2. Design
In a repeated measures design, all participants learned two parallel
probabilistic sequences in separate test sessions, one on and the other
oﬀ medication, with their order counterbalanced and at least one week
apart. The mean time oﬀ medication before testing was 11.33 h
(SD=1.6, ranging from 9 to 14 h withdrawal).
2.3. Procedure
2.3.1. Apparatus and probabilistic serial reaction time task
Stimulus presentation, response recording and RT measurement
were performed using a Dell laptop PC with a 15.1″ TFT monitor and
an ergonomically designed button box (see Fig. 1). The four response
buttons were arranged horizontally (and are labelled as 1–4 from left to
right).
Participants performed a four-choice SRTT comprising 15 blocks of
100 trials. The beginning of each trial was signalled by the appearance
of a black 'X' (17 mm) in the centre of one of four boxes (26 mm square
with a black outline and white background), which were evenly spaced
(17 mm separation) across the horizontal mid-line of the grey display.
Participants were instructed to respond to the location of the target by
pressing the corresponding button on the response box as quickly and
accurately as possible. Their response triggered the removal of the
target cross and its appearance (after 400 ms) at the next location. At
the end of each block participants were required to press a button when
they were ready to continue.
Target locations in each session were selected from one of two pairs
of second order conditional sequences (SOCS) in which determining
the current location requires as a minimum knowledge of the previous
two locations. (Pair 1 is SOC1=3-1-4-3-2-4-2-1-3-4-1-2 and SOC2=4-
3-1-2-4-1-3-2-1-4-2–3, pair 2 is SOC3=1–2-1-4-3-2-4-1-3-4-2-3 and
SOC 4=3-2-3-4-1-2-4-3-1-4-2-1.) Sequences were created according to
rules proposed by Reed and Johnston (1994). Half of the participants
in each session (on vs. oﬀ medication) were randomly assigned either
to pair 1 or 2 and received the other pair in their next session. In each
testing session, the SOC sequence participants were expected to learn
was presented with an 85% probability and so is referred to as the
probable SOC. The other paired SOC was presented on the remaining
15% of trials, and is referred to as the improbable SOC. The next
location was selected from the relevant SOC using the same probabil-
istic rule (i.e. two most recent target locations). For example, for a
participant trained on SOC1, the locations 4 & 1 were followed by
either a target at location 2 (following the probable sequence SOC1)
with a probability of.85 or a target at location 3 (following the
improbable paired sequence SOC2) with a probability of.15. Each
block began at a random point in the sequence and the SOCs used as
probable or improbable trials were counterbalanced across partici-
pants.
Reaction times (RT) were measured in milliseconds from the onset
of the target to initiation of a response. For each participant, median
RTs and errors for both probable and improbable trials in each block
were calculated. In the analysis, RTs were included for both correct and
incorrect responses, as a large proportion of errors, especially oﬀ-
medication, are likely due to simple diﬃculties in kinetic control rather
than incorrect response selection, and allows comparison with pre-
viously published studies (see Wilkinson and Jahanshahi (2007)).
2.3.2. Tests of awareness
At the end of the second testing session following completion of the
SRTT task, awareness of the sequence was assessed by two sets of tests:
the process dissociation procedure and a recognition test. These involve
informing the participant of the presence of the sequence and so could
not be performed in session 1 without revealing the nature of the study.
The process dissociation procedure (PDP) determines whether the
generation of knowledge of the probable sequence was under inten-
tional control (and therefore conscious). Following the ﬁnal SRTT
block of learning in session 2, participants were informed that during
the training blocks the targets had appeared in a repeating sequence.
For 12 of the 24 test trials participants observed short test sequences of
ﬁve targets taken from the probable sequence to which they responded
as they had previously. Then, they were instructed to press a button
indicating the next item in the sequence (inclusion test, I). For the
remaining 12 trials participants had to produce a single key press that
did not overlap with the probable sequence (exclusion test, E). The
recognition test involved identifying chunks from the training se-
quence. Before the test, participants were told they would be presented
with short sequences of 6 target locations some of which were part of
the training sequence and some were not. Participants were requested
to respond to each target, judge whether the sequence was old or new
and rate of how conﬁdent they were in their judgement. Ratings were
made by clicking on option buttons labelled “old” and “new” and then
on buttons labelled “sure,” “fairly sure,” and “guess.”
3. Results
3.1. Probabilistic sequence learning
Fig. 2 shows mean of the median RTs for patients on (Fig. 2a) and
oﬀ (Fig. 2b) dopaminergic medication across 15 blocks of trials. A four-
way ANOVA was performed on median RTs with Medication (on vs.
oﬀ), Probability (probable vs. improbable trials), and Block (1–15) as
within subjects variables and Order (session 1 vs. session2). As the
results showed that neither the main eﬀect nor any interactions
involving order were signiﬁcant (P > 0.1) the analysis was repeated as
a three-way ANOVA excluding this factor. Participants were slower on
improbable than probable conditions (Probability: F(1,14)=16.77, p
< .001), which indicates the presence of learning. There were also
signiﬁcant interactions between Medication x Probability: F(1,14)=4.9,
(p=.044), indicating that the extent of learning (i.e. diﬀerence between
improbable and probable trials) diﬀered signiﬁcantly between medica-
tion states. Additionally, there was a signiﬁcant interaction between
Probability x Block: F(14,196)=2.89, (p=.001), which is indicative of a
generalised increase in learning across blocks. No other main eﬀects or
interactions were signiﬁcant (p > .10).
To fully explore the two signiﬁcant interactions a direct measure of
learning was derived by calculating the mean diﬀerences between
probable and improbable scores. To illustrate the basis for the
Medication x Probability interaction the mean diﬀerence score in the
Table 1
Demographic and clinical characteristics of Parkinson's disease patients who took part in
the study. SD=standard deviation, UPDRS-III: motor section of the Unified Parkinson's
Disease Rating Scale. NB: Data marked with an asterisk was unavailable for participant
15.
PD Patients (n=15) Mean SD
Age (years) 67.07 6.06
Disease duration (years)* 8.86 5.25
UPDR-III ON* 15.00 8.75
UPDRS-III OFF* 30.79 13.81
Levodopa equivalent daily dosage 694.89 462.44
Length of Medication Withdrawal (Hours) 12.88 2.20
Hoehn and Yahr stage of illness 1.75 .67
National Adult Reading Test Predicted IQ* 92.83 8.39
Mini Mental State Examination (range 0–30) 29.43 .76
Beck Depression Inventory (range 0–63)* 7.43 3.65
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two medication states are plotted in Fig. 3a, which clearly shows that
learning was far higher when patients were tested in the on medication
condition. To illustrate the Probability x Block interaction diﬀerence
score were calculated on a block-by-block basis and averaged across the
two medication conditions (see Fig. 3b). The Page trend test was then
used to assess whether learning tended to increase over the blocks
using the large sample adjustment (Page, 1963). The results revealed a
signiﬁcant trend for increased learning across blocks (L=10.9, p
< .001).
The patient data was then compared to controls separately for the
on and oﬀ medication conditions in separate ANOVAs. However, it
should be noted that the primary motivation of this study was a
repeated measures patient design with an independent variable
(medication) that cannot easily be tested in controls and is further
complicated by being counterbalanced across the testing sessions.
Speciﬁcally, the timing of the medication conditions was counter-
balanced so that half of the patients received medication at testing time
1 and the other half at time 2 and so each group comprised patients
tested at the two times (i.e. testing time is a between group variable). A
control comparison group was created by randomly selecting 50% of
the participants and using their data gathered at time 1 with the
remainder of the control group comprising the time 2 data from the
other patients. Patients and controls were compared using a four factor
mixed ANOVA with Probability and Block as within participant factors
and Group (Patient vs. Control) and test order (time 1 vs time 2) as
between participant factors. In both cases learning was conﬁrmed by a
main eﬀect of probability when comparing controls with patients On-
(F(1, 24)=20.18, p < .001) and Oﬀ- (F(1, 24)=8.01, p=.008) medica-
tion. Furthermore, the development of this learning over time is
demonstrated by the Probability x Block interaction in both On-
(F(14, 336)=1.77, p=.044) and Oﬀ- (F(14, 336)=3.54, p < .001)
comparisons. In neither case did patients diﬀer signiﬁcantly from
controls, On- (F(1, 24)=1.68, p=.208) and Oﬀ- (F(1, 24)=2.43, p=.132)
medication. There were no other signiﬁcant main eﬀects or interac-
tions. We also repeated the analysis using the reverse grouping of
control data (e.g. creating a group with the time 1 and time 2 data not
included in the original analysis). The analysis produced exactly the
same pattern of signiﬁcant and non-signiﬁcant results. Additionally, we
also analysed the whole control sample using a three way ANOVA (with
Probability, Block and Order as factors) to see if there were any
indications of order eﬀects. There was no main eﬀect of Order nor any
interactions between Probability and Order (alone or in combination
with Block).
A three-way ANOVA with Medication (on vs. oﬀ), Probability
(probable vs. improbable trials) and Block (1−15) as the within subject
factors was performed on mean percentage errors and revealed neither
signiﬁcant main eﬀects nor any interactions (p > .1).
3.2. Tests of awareness
3.2.1. Process dissociation procedure (PDP)
Task performance in the inclusion (I) and exclusion (E) tests was
scored by calculating the number of sequences that were completed
with an item from the probable (trained) SOC (Wilkinson and
Fig. 1. Illustration of the button box used with an example of the stimuli presented on
the monitor.
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Fig. 2. a and b: Mean of the median reaction times in milliseconds (ms) for probable and improbable trials, plotted separately for patients with Parkinson's disease on (2a) and oﬀ (2b)
levodopa medication across 15 blocks of the Serial RT task. Error bars represent one standard error of the mean.
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Jahanshahi, 2007). A signiﬁcant diﬀerence between the inclusion and
exclusions score would indicate that participants had control over the
expression or withholding of their knowledge, providing performance
in either condition was not at chance. To estimate baseline perfor-
mance, the number of sequences that were completed with an item
from the improbable SOC were calculated for both tests. Fig. 4 shows
the number of probable versus improbable sequence completions in the
inclusion and exclusion tests for each medication condition. The data
was analysed using a three-way ANOVA with Task (inclusion vs.
exclusion), Sequence (probable vs. improbable) and Medication (on
vs. oﬀ) as a within groups variable. No main eﬀects or interactions were
signiﬁcant (Task, F(1,12)=2.411), Sequence, F(1,12)=.261,
Medication, F(1,12)=.103, Task x Medication, F(1,12)=.151,
Sequence x Medication, F(1,12)=1.265, Task x Sequence, F(1,13)
=.305, Task x Sequence x Medication, F(1,13)=.128. Participants were
equally likely to select items from the probable SOC whether they were
trying to complete the sequence under inclusion conditions or delib-
erately trying to avoid probable items under exclusion instructions.
They also completed sequences using a similar number of items from
the improbable sequence (e.g. responses were equally distributed).
Therefore, we conclude the PDP shows no evidence that participants
had developed awareness of the sequences.
3.2.2. Recognition test
Responses and certainty judgements on the recognition test were
classiﬁed according to the following criteria 1= certain new, 2= fairly
certain new, 3=guess new, 4=guess old, 5=fairly certain old and 6=
certain old. Separate mean scores were calculated for probable and
improbable sequences with the expectation that probable sequences
were more likely to be judged as old (previously encountered se-
quences) than improbable sequences. A two-way ANOVA with se-
quence (probable vs. improbable) as the within subject variables and
Medication (on vs. oﬀ) as the between groups variable revealed no
signiﬁcant eﬀects of either Sequence (F(1,12)=.526) or Medication,
(F(1,12)=1.456) nor any interaction between (F(1,12)=1.015) them,
and so there is no evidence of explicit sequence knowledge (Fig. 5).
4. Discussion
Patients with Parkinson's disease showed signiﬁcantly greater
incidental sequence learning on an incidental probabilistic SRTT while
tested on dopaminergic medication than when assessed oﬀmedication.
Fig. 3. a and b. Mean RT diﬀerence scores (improbable minus probable reaction times) plotted (a) as an overall mean across blocks for each of the two medication conditions and (b) for
blocks 1–15 collapsed across medication conditions.
Fig. 4. Mean number of test chunks completed with either the ﬁnal item of a triplet from the trained sequence (old) or an untrained sequence (new) on and oﬀ levodopa medication.
Completions were calculated out of a possible 12 that could have been achieved in the inclusion and exclusion tests. Error bars represent one standard error of the mean.
M. Beigi et al. Neuropsychologia 93 (2016) 53–60
57
This ﬁnding was, in large part, attributable to a marked attenuation of
learning in the oﬀ-medication condition. Crucially, there was no
evidence for any signiﬁcant overall diﬀerence in RTs between the
medication conditions, which makes it unlikely that diﬀerences in
learning on and oﬀ medication can be simply explained by greater
motor diﬃculties when oﬀ medication. Furthermore, as indicated by
the absence of main eﬀects of block, there was no evidence for
performance improvements based simply on practice or task familiarity
eﬀects. Importantly, in all conditions there was an interaction between
block and probability, which was attributable to a trend for increased
learning with time in all conditions. As a consequence, the results
clearly indicate that the administration of levodopa to PD patients can,
at least in part, ameliorate deﬁcits in incidental sequence learning
associated with the disease.
In general when we compared patient performance to normal
control data we found no evidence of impairment on- or oﬀ- medica-
tion. In part, this supports the rationale of this study that the eﬀects of
the disease versus those of medication is best understood using a
within participant design, which has greater sensitivity within a
heterogeneous patient group. Though, as noted here comparing such
studies to control data can be challenging as certain conditions cannot
reasonably replicated (e.g. medication).
These ﬁndings add to mounting evidence regarding the importance
of dopamine during incidental sequence learning tasks, such as the
SRTT (Badgaiyan et al., 2007; Jackson et al., 1995). The current study
extends earlier results by demonstrating that considerable attenuation,
but not complete abolition, of PD patients’ ability to learn incidental
motor sequences can occur as a consequence of the disease. This result
was shown through the highly signiﬁcant diﬀerence between patients
on and oﬀ medication, but the failure of either of these groups to diﬀer
from controls indicates the importance of within group comparisons in
understanding the eﬀects of medication. Interestingly, the opposite
pattern of results were reported in a study looking at intentionalmotor
sequence learning using an SRTT task (Kwak et al., 2010). In their task
patients on medication were speciﬁcally impaired during early trials
where learning was being established compared with either the same
group oﬀ-medication or the performance of age-matched control
participants. However, participants were informed they would be
learning short (6-item) motor sequences, and were even shown the
sequence in a preview period before training. In contrast, in the current
study participants were not informed of the presence of the sequence
and showed no objective evidence of awareness of the sequence
structure at the end of training (likely due to the more complex
sequence structure and probabilistic presentation).
The current result is consistent with previous studies of probabil-
istic sequence learning in PD that reported no evidence of awareness of
the sequence (Wilkinson and Jahanshahi, 2007; Wilkinson et al.,
2009). Importantly, task awareness might also account for diﬀerences
between the current study and previous studies of motor sequence
learning in which PD patients were explicitly instructed and aware they
were to learn a sequence. For example, a series of studies have
investigated the impact of levodopa (Carbon et al., 2003; Feigin
et al., 2003; Ghilardi et al., 2007) on sequence learning in a reaching
paradigm in which a cursor is moved to a sequence of 8 target
locations. The results indicated that explicit learning of the target
sequences during testing was no diﬀerent for the on vs. oﬀ medication
conditions, but that declarative knowledge was greater in the dopamine
depleted state (Feigin et al., 2003; Ghilardi et al., 2007). In the task
used in these studies, PD patients would have engaged mechanisms for
intentional and goal-directed learning, which may diﬀer from the
incidental learning of sequences in the present study. This would also
account for the diﬀerences between the current study and the SRTT
study of Kwak et al. (2010). Taken together, the results across these
studies indicate the heterogeneity of motor learning tasks in their
dependence upon brain regions where dopamine is depleted in PD. As
a consequence, care should be taken when generalising ﬁndings, e.g.
suggesting that results apply across all motor sequence learning when
only incidental learning has been assessed.
In general, the degeneration of dopamine production in PD follows
a distinctive spatial-temporal gradient with the greatest loss of DA
neurons in early stages occurring in the lateral ventral tier of substantia
nigra pars compacta (SNpc) that enervates the dorsal striatum
(Fearnley and Lees, 1991; Kish et al., 1988). In contrast, in early PD,
dopamine activity is relatively preserved in ventral striatal areas and
the cortical areas to which they are interconnected, that is the anterior
cingulate, inferior temporal cortex and the orbitofrontal cortex (OFC).
Of particular relevance to the current study are reviews of the literature
arguing that diﬀerential eﬀects of dopaminergic medication within the
dorsal (improved by L-dopa administration) and ventral striatum
(impaired by an ‘overdose’ of L-dopa medication) may have speciﬁc
implications for learning (Cools, 2006; Macdonald and Monchi, 2011).
In terms of motor learning, it has been argued that skill acquisition is
critically dependent on the ventral striatum and skill performance on
the dorsal striatum (Atallah et al., 2007). More recently, MacDonald
et al. (2011, 2013) have reﬁned this dichotomy suggesting that the
ventral striatum mediates memory encoding (for both explicit and
implicit tasks) whilst the dorsal stratum is involved in memory retrieval
once a skill is learned.
The current study, however, indicates that dysfunction of the dorsal
striatum as in PD also has implications for motor skill learning. By
providing a continuous measure of learning throughout the task (e.g.
learning as indexed by RT diﬀerences between probable and improb-
able sequences across trials), the current paradigm is ideal for
identifying diﬃculties in acquisition as opposed to retrieval of well-
established learning. The absence of a consistent diﬀerence between
the probable and improbable sequence trials across all blocks in the oﬀ
medication condition is strong evidence that patients are failing to
learn the probable sequence in this oﬀ state. This contrasts with
paradigms that test learning at the end of the practice period which
may be testing the retrieval of established learning. Additionally, the
similar RTs between patients on and oﬀ medication provide further
evidence that impairments are not attributable to a retrieval diﬃculty.
Nonetheless, even though patients were more greatly impaired oﬀ
medication this does not mean that they were unimpaired when on
Fig. 5. Mean recognition ratings for old and new test sequences on and oﬀ levodopa
medication. Participants responded to 12 old and 12 new sequences and made a
recognition judgement for each sequence (1=certain new, 6=certain old).
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medication. Indeed, Wilkinson et al. (2009) have previously shown
using the same probabilistic learning task that PD patients on medica-
tion demonstrate less learning than age matched controls. Therefore,
the results do not preclude the involvement of the ventral striatum in
sequence learning.
In conclusion, the present study established for the ﬁrst time that
levodopa medication enhanced incidental learning by patients with PD
on a probabilistic sequence learning paradigm even though the patients
were not aware of the existence of the sequence or their acquired
knowledge. The results suggest a role in incidental motor sequence
learning for dorsal striatal areas strongly aﬀected by dopamine deple-
tion in early PD.
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